<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Meprobamate poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Meprobamate poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Meprobamate poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Bodmer, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alessandro Ceschi, MD, MSc, FEAPCCT</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22062982"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> is a sedative and anxiolytic medication that was marketed for decades in the United States and Europe. The first case of meprobamate poisoning was described in 1956 [<a href="#rid1">1</a>]. Due to its substantial abuse potential, meprobamate is no longer recommended for treatment of insomnia and has been replaced by benzodiazepines and other agents. Although use of the drug is declining, significant meprobamate overdose remains a life-threatening emergency.</p><p>This topic will review the basic pharmacology, clinical presentation, and management of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning. Discussions of the general approach to the management of poisoned patients and detailed management of other toxins are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="headingAnchor" id="H25734165"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> poisoning is rare and most cases involve suicide attempts [<a href="#rid2">2</a>]. In France, meprobamate has been used more widely and the drug was involved in approximately 7 percent of psychotropic poisonings in 2005 [<a href="#rid3">3</a>]. Mortality in cases of overdose has ranged between 1.7 and 5 percent [<a href="#rid4">4-6</a>]. Meprobamate ingestion is associated with an increased risk of intensive care unit (ICU) admission (adjusted odds ratio [OR] = 2.71; 95% CI: 1.27-5.81) [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H22063040"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> is a carbamate which acts primarily as a sedative by increasing GABA<sub>A</sub>-mediated neurotransmission in a manner similar to barbiturates [<a href="#rid8">8,9</a>]. <a class="drug drug_general" data-topicid="9205" href="/z/d/drug information/9205.html" rel="external">Carisoprodol</a>, prescribed as a centrally acting muscle relaxant, is mainly metabolized to meprobamate by cytochrome P450 2C19, shares properties with meprobamate, and also has significant potential for abuse [<a href="#rid10">10-12</a>].</p><p class="headingAnchor" id="H22063047"><span class="h1">PHARMACOKINETICS AND TOXICOKINETICS</span><span class="headingEndMark"> — </span>After oral ingestion of a therapeutic dose, <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations are reached within one to three hours [<a href="#rid13">13,14</a>]. Protein binding is negligible (14 to 24 percent). The drug’s volume of distribution is reported to be 0.70 L/kg, and is not significantly altered in overdose. A standard single therapeutic dose for an adult ranges from 200 to 800 mg. Significant toxicity is likely with ingestions of 4 to 5 g or more [<a href="#rid3">3,4</a>]. </p><p><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> is primarily metabolized in the liver to inactive metabolites [<a href="#rid15">15,16</a>], although 10 to 20 percent of the parent compound is excreted unmetabolized by the kidneys [<a href="#rid16">16</a>]. Elimination is by first order pharmacokinetics and reported elimination half-lives range between 6.4 and 16.6 hours with therapeutic doses [<a href="#rid17">17,18</a>] with little change in overdose [<a href="#rid17">17,19</a>]. </p><p class="headingAnchor" id="H22063054"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span></p><p class="headingAnchor" id="H22063062"><span class="h2">History</span><span class="headingEndMark"> — </span>In the setting of a drug overdose, an accurate history can be difficult to obtain. However, whenever possible, the clinician should try to learn from the patient and any others who may be knowledgeable (eg, friends, paramedics) about the circumstances of the <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> ingestion. Features of special concern include other comorbidities (particularly heart failure or other cardiac disease), whether the ingestion was intentional, the amount ingested, the time elapsed since the ingestion, and whether other substances were also taken. There is no data that accurately describes the correlation between the amount ingested and the severity of symptoms, but the case fatality rate for meprobamate poisoning is low. Significant toxicity is likely with ingestions of 4 to 5 g or more [<a href="#rid3">3,4</a>]. Meprobamate is often ingested with benzodiazepine [<a href="#rid4">4</a>]. (See <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p class="headingAnchor" id="H22063083"><span class="h2">Clinical symptoms and signs</span></p><p class="headingAnchor" id="H54858695"><span class="h3">Overview</span><span class="headingEndMark"> — </span>The onset of symptoms from <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning usually occurs within 20 to 30 minutes of ingestion [<a href="#rid2">2-6</a>]. Most important among the signs of poisoning are hypotension and depressed mental status. Potential signs of poisoning are myriad but primarily related to depression of the central nervous, cardiovascular, and respiratory systems. Symptoms and signs may include: drowsiness, weakness, ataxia, paresthesias, headaches, vision disturbances, seizures, stupor, coma, nausea and vomiting, respiratory depression, pulmonary edema, respiratory arrest, arrhythmias (both bradycardia and tachycardia), and shock.</p><p class="headingAnchor" id="H25734757"><span class="h3">Cardiovascular</span><span class="headingEndMark"> — </span>Hypotension is a hallmark of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning and is generally ascribed to myocardial depression [<a href="#rid3">3,5,20-23</a>]; vasoplegia (decreased peripheral vascular resistance) is a less likely explanation. Hypotension can be profound, and death from meprobamate overdose is most often due to cardiovascular collapse. </p><p>Myocardial depression has been demonstrated on echocardiogram in a number of case reports. A case series of 74 patients with severe <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning requiring mechanical ventilation reported that 29 (40 percent) exhibited hypotension with a decreased left ventricular ejection fraction (LVEF, 45±15 percent) and decreased cardiac index (2.0±0.7 L/minute/m<sup>2</sup>) on echocardiography [<a href="#rid3">3</a>]. Twenty-eight of the 29 hypotensive patients required treatment with vasopressors.</p><p class="headingAnchor" id="H25734764"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>Altered mental status with significant central nervous system (CNS) depression is frequently described in <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning [<a href="#rid4">4,6</a>]. In one retrospective case series of 146 cases, more than 80 percent of patients had a Glasgow Coma Scale (GCS) score ≤7, although most patients in this series had ingested additional sedatives (primarily aceprometazine) [<a href="#rid6">6</a>]. In another series of 59 confirmed meprobamate ingestions, the mean GCS was 7.1±1 [<a href="#rid4">4</a>]. The duration of coma can vary from an hour or two to a few days depending upon the severity of the overdose. Coma from severe meprobamate overdose associated with an absence of electrical brain activity (electroencephalographic silence) has been described in several case reports [<a href="#rid24">24-26</a>]. </p><p>Other neurologic manifestations of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning may include decreased muscle tone and loss of deep tendon reflexes [<a href="#rid4">4,21</a>]. </p><p class="headingAnchor" id="H4416234"><span class="h3">Respiratory</span><span class="headingEndMark"> — </span>Cases of respiratory failure and pulmonary edema associated with <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning have been reported [<a href="#rid21">21,27,28</a>]. In most cases, the cause of respiratory failure is likely multifactorial and may include direct depression of the respiratory centers of the brain, prolonged myocardial depression, aspiration, and the development of acute respiratory distress syndrome. In addition, patients with meprobamate poisoning have often ingested other agents that contribute to respiratory depression, such as benzodiazepines and alcohol.</p><p class="headingAnchor" id="H54859003"><span class="h3">Other manifestations</span><span class="headingEndMark"> — </span>Cases of rhabdomyolysis [<a href="#rid29">29</a>], pancreatitis [<a href="#rid30">30,31</a>], and hypothermia have been described in association with <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning, but a causal relationship remains speculative. Bezoar formation can occur [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H54859281"><span class="h1">DIAGNOSTIC IMAGING</span><span class="headingEndMark"> — </span>In cases of suspected <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning, a bedside transthoracic ultrasound or echocardiogram can assist with diagnosis by demonstrating depressed myocardial function (diminished ejection fraction). A plain chest radiograph should be obtained if pulmonary edema is suspected.</p><p class="headingAnchor" id="H22063097"><span class="h1">LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H54859017"><span class="h2">Testing for meprobamate</span><span class="headingEndMark"> — </span>Analytical methods for the identification and quantification of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> in the blood and urine are available [<a href="#rid33">33,34</a>]. However, rapid laboratory testing in the emergency setting typically cannot be performed and thus plays no role in the management of acute overdose. </p><p>There is an association between the severity of central nervous system (CNS) depression and serum <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> concentrations [<a href="#rid4">4</a>]. In a review of 59 cases of meprobamate overdose, patients with a Glasgow Coma Scale (GCS) score of 13 to 15 (n = 8) had a mean concentration of 63 mg/L, patients whose GCS score ranged from 9 to 12 (n = 9) had a mean concentration of 81 mg/L, and patients whose GCS score ranged from 3 to 5 (n = 42) had a mean concentration of 111 mg/L [<a href="#rid4">4</a>]. Nevertheless, a clear correlation between clinical presentation and serum concentration is far from established, and concentrations are not required to guide therapy. </p><p class="headingAnchor" id="H54859010"><span class="h2">General evaluation</span><span class="headingEndMark"> — </span>Routine laboratory evaluation of the patient with suspected <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning generally includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count, basic serum electrolytes, and serum BUN and creatinine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of altered mental status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate levels, to rule out these common co-ingestants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram, to rule out conduction system abnormalities (eg, QRS or QTc interval prolongation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood and urine samples for further toxicologic analyses if needed.</p><p></p><p>In patients with manifestations of a significant <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning (eg, hypotension, altered mental status), we obtain a serum lactate concentration, arterial or venous blood gas, liver transaminases (AST, ALT), lipase, and creatine phosphokinase.</p><p class="headingAnchor" id="H25734650"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Although a definitive diagnosis of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning can be made with serum testing, typically such methods are not available to the emergency or critical care clinician managing the acutely ill patient. Most often, the diagnosis is made clinically on the basis of a history of ingestion (often intentional) when available and suggestive clinical findings, such as depressed mental status, hypotension from myocardial depression, and possibly depressed respiration. A transthoracic ultrasound or echocardiogram is useful for confirming myocardial depression as the cause of hypotension. </p><p class="headingAnchor" id="H25734663"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning includes overdose with sedative-hypnotics, such as barbiturates and benzodiazepines, <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a>, alcohol, and other central nervous system (CNS) depressants. Although seldom an issue in clinical practice, medical conditions that cause both depressed mental status and hypotension without other prominent signs could be confused with meprobamate poisoning. Such conditions include severe hypothyroidism, adrenal insufficiency, and hypopituitarism. Common causes of depressed mental status, such as hypoglycemia, intracerebral hemorrhage, stroke, seizure (eg, postictal state), and sepsis should be considered in the differential diagnosis. These conditions can generally be distinguished readily from meprobamate poisoning on the basis of the history, examination findings (eg, focal neurologic deficits with stroke; signs of infection with sepsis), basic laboratory tests (eg, finger stick glucose), or when necessary diagnostic imaging. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1594.html" rel="external">"Definition, classification, etiology, and pathophysiology of shock in adults"</a>.)</p><p>The combination of marked central nervous system depression, hypotension, and myocardial depression distinguishes <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning clinically from most other toxic ingestions, with the exception of barbiturate poisoning. Severe CNS depression, hypothermia, and respiratory depression are the characteristic signs of barbiturate poisoning. Cutaneous bullae (“barb blisters”) have been described in association with barbiturate poisoning [<a href="#rid35">35,36</a>], but blisters cannot reliably distinguish the two poisonings. When clear differentiation is necessary, serum concentration measurements are usually needed.</p><p class="headingAnchor" id="H22063004"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H22063012"><span class="h2">Initial stabilization</span><span class="headingEndMark"> — </span>Initial assessment of the poisoned patient is described separately; details related to the management of the patient with <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning are discussed here. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Initial evaluation and treatment'</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p>Management begins with rapid assessment of the patient's airway, breathing, and circulation, and these are secured as necessary. Central nervous system depression is a hallmark of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning and respiratory compromise can also occur, so early tracheal intubation may be required. Intubation is generally needed due to a decline in mental status and the resulting loss of airway protection, rather than isolated respiratory depression. Given the risk of myocardial depression and severe hypotension in these patients, <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a> and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> are the preferred induction agents for rapid sequence intubation. Common causes of altered mental status should be ruled out (eg, fingerstick glucose measurement for hypoglycemia). Continuous cardiac monitoring and pulse oximetry should be performed. (See  <a class="medical medical_review" href="/z/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.)</p><p><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> poisoning is potentially life-threatening but the drug is readily removed by hemodialysis or other forms of extracorporeal elimination. Therefore, we recommend that immediate nephrology consultation be obtained for any patient with a severe meprobamate poisoning (eg, severely depressed mental status, respiratory problems requiring intubation, hypotension requiring treatment with a vasopressor). (See <a class="local">'Enhanced elimination'</a> below.)</p><p class="headingAnchor" id="H4416589"><span class="h2">Treatment of hypotension</span><span class="headingEndMark"> — </span>As hypotension from <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning is due primarily to myocardial depression, clinicians must approach fluid resuscitation cautiously. Intravenous boluses of isotonic fluid are given to maintain intravascular volume, but fluid overload must be avoided. Vasopressor support may be needed to treat hypotension. In such cases, we suggest starting with <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>. If needed to maintain adequate mean arterial pressure, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> may be added. The authors prefer to avoid <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> due to the risk of arrhythmia. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a> and  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.) </p><p>Start a <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> infusion at 2.5 µg/kg per minute and titrate to effect, using mean arterial pressure, urine output, skin findings (eg, skin temperature, capillary refill), and serum lactate concentrations as markers for perfusion. The rate of the dobutamine infusion can be increased up to 10 µg/kg per minute. In the authors’ experience, larger doses have not improved outcomes. If necessary, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> can be added at a starting dose of 2 to 5 µg/minute and titrated upwards as needed. For shock that is refractory to intravascular volume repletion, dobutamine, and norepinephrine, additional treatments can include <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (bolus doses and an infusion can be given) and mechanical assist devices such as an intra-aortic balloon pump or intraventricular pump. In cases of refractory hypotension, we recommend obtaining an echocardiogram to assess cardiac function.</p><p class="headingAnchor" id="H22063019"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>There are no controlled trials that explore the efficacy and safety of either gastric lavage or activated charcoal for the treatment of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning. We do not routinely recommend gastric lavage but do suggest administration of a single dose of activated charcoal if the patient presents within one hour of a significant meprobamate ingestion (eg, patient is symptomatic; ingestion ≥4 to 5 g) and the airway is secure (ie, patient is alert or tracheal tube is in place). </p><p>We do not routinely suggest the use of multidose activated charcoal. However, a case series of two patients given two treatments each of activated charcoal reported an average elimination half-life of 4.5 hours [<a href="#rid37">37</a>], which is considerably shorter than those commonly reported in therapeutic dose and overdose [<a href="#rid17">17-19</a>].</p><p>Although rare, bezoar formation has been reported after ingestion of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> [<a href="#rid32">32,38,39</a>]. Bezoar formation may be suspected following a massive overdose or in patients with persistent signs of poisoning (eg, prolonged refractory hypotension). Diagnosis may be made on the basis of imaging studies (plain abdominal radiograph, computed tomography, ultrasound). In addition, if such testing is available, serial serum meprobamate concentrations may be helpful as a consistently elevated or rising level would suggest the presence of a bezoar causing ongoing absorption of drug from the gastrointestinal tract. Consultation with a gastroenterologist and surgeon should be obtained if a bezoar is suspected or identified in order to arrange for endoscopic or surgical removal. (See  <a class="medical medical_review" href="/z/d/html/2535.html" rel="external">"Gastric bezoars"</a>.)</p><p class="headingAnchor" id="H22063026"><span class="h2">Enhanced elimination</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> exhibits low protein binding and is efficiently removed by high flux hemodialysis and other forms of extracorporeal elimination [<a href="#rid27">27</a>]. We recommend that immediate nephrology consultation be obtained for any patient with a severe meprobamate poisoning (eg, severely depressed mental status, respiratory problems requiring intubation, hypotension requiring treatment with a vasopressor) in order to initiate extracorporeal removal as quickly as possible. The best method for removal will vary depending upon available resources and local expertise. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Extracorporeal removal'</a> and  <a class="medical medical_review" href="/z/d/html/1854.html" rel="external">"Acute hemodialysis prescription"</a>.)</p><p>Although multiple techniques to enhance the elimination of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> have been described, reports are largely limited to small case series. Proposed techniques include resin and charcoal hemoperfusion [<a href="#rid19">19,40-42</a>], hemodialysis [<a href="#rid13">13,20,27</a>], peritoneal dialysis [<a href="#rid43">43</a>], and combined hemodialysis-hemoperfusion [<a href="#rid13">13</a>]. The authors have used hemodiafiltration successfully to remove meprobamate from poisoned patients. Values reported for plasma clearance for charcoal hemoperfusion have ranged between 134 and 164 mL/minute [<a href="#rid19">19</a>], a range of 162 to 222 mL/minute was reported for resin hemoperfusion [<a href="#rid41">41</a>], and a rate of 62 mL/minute was reported for hemodialysis in one case [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H22063033"><span class="h2">Ongoing treatment and disposition</span><span class="headingEndMark"> — </span>Ongoing treatment of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning is largely supportive as no antidote is available. There are no controlled studies to inform treatment decisions. Airway protection and mechanical ventilation are vital in cases of significant central nervous system depression or respiratory compromise. The extent of any pulmonary injury and baseline function determine the approach to mechanical ventilation. (See  <a class="medical medical_review" href="/z/d/html/277.html" rel="external">"Mechanical ventilation of adults in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p>Hypotension is managed with judicious administration of IV isotonic crystalloid and vasopressor support as needed. In case of refractory hypotension, we recommend obtaining an echocardiogram to assess cardiac function. Nephrology consultation should be obtained for any severe poisoning to expedite extracorporeal removal. (See <a class="local">'Treatment of hypotension'</a> above and <a class="local">'Enhanced elimination'</a> above.)</p><p>Any patient with signs of severe <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning should be admitted to an intensive care setting. There are no systematic data to guide the management of mildly symptomatic or asymptomatic patients with purported meprobamate ingestion. Patients with minor symptoms or signs (eg, mild drowsiness but airway reflexes intact and blood pressure stable) should be observed in a monitored setting until these findings resolve. We suggest close monitoring of such patients including pulse oximetry, cardiac monitor, and reassessment of vital signs and a focused neurologic evaluation every 30 to 60 minutes. Patients whose clinical status worsens should be transferred to an intensive care setting; those whose symptoms resolve should undergo a psychiatric evaluation. </p><p>With the exception of patients with a massive ingestion complicated by bezoar formation, patients who have ingested <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> should manifest symptoms within three hours, as gastrointestinal absorption is rapid and peak serum concentrations are achieved within one to three hours. Therefore, we suggest that asymptomatic patients with a reported meprobamate overdose be observed for four to six hours to provide a margin of safety; they may be discharged or referred for psychiatric evaluation if they remain without clinical signs or symptoms and their reexamination is unremarkable. Patients who develop signs of overdose are admitted to the appropriate monitored setting. Appropriate psychiatric evaluation is needed for all patients whose overdose was intentional. </p><p class="headingAnchor" id="H22062997"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2092955832"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical and/or medical toxicologists available for bedside consultation and/or inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H757103352"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H22062989"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> poisoning is rare and occurs most often from intentional overdose. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> poisoning causes central nervous system depression, which may result in coma, and myocardial depression, which can produce significant hypotension.</p><p></p><p class="bulletIndent1">The onset of symptoms occurs within 20 to 30 minutes of ingestion. The most important signs of a significant poisoning are hypotension and depressed mental status. Other symptoms and signs may include: drowsiness, weakness, ataxia, headaches, vision disturbances, seizures, stupor, coma, vomiting, respiratory depression, pulmonary edema, respiratory arrest, arrhythmias (both bradycardia and tachycardia), and shock. (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> poisoning includes overdose of sedative-hypnotic drugs, such as benzodiazepines and barbiturates, drugs with sedative-like effects (eg, <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a>), alcohols, and medical conditions that cause coma and hypotension. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation and diagnostic imaging</strong> – The necessary laboratory workup is described in the text. We suggest performing echocardiography to assess myocardial depression in significant poisoning causing systemic hypotension. (See <a class="local">'Laboratory evaluation'</a> above and <a class="local">'Diagnostic imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of severe overdose</strong> – Death from <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">meprobamate</a> overdose results from cardiovascular collapse or respiratory failure. Securing the airway early is crucial. Blood pressure is maintained by careful administration of IV crystalloids to maintain circulating volume, while avoiding fluid overload, and vasopressor support when necessary. We suggest initiating treatment with <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, when vasopressor support is needed (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial stabilization'</a> above and <a class="local">'Treatment of hypotension'</a> above and <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced elimination including hemodialysis</strong> – <a class="drug drug_general" data-topicid="9611" href="/z/d/drug information/9611.html" rel="external">Meprobamate</a> is efficiently removed by high flux hemodialysis and other forms of extracorporeal elimination. We recommend that immediate nephrology consultation be obtained for any patient with a severe meprobamate poisoning (eg, severely depressed mental status, respiratory problems requiring intubation, or hypotension requiring treatment with a vasopressor) in order to initiate extracorporeal removal as quickly as possible. (See <a class="local">'Enhanced elimination'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">SHANE AM, HIRSCH S. Three cases of meprobamate poisoning. Can Med Assoc J 1956; 74:908.</a></li><li><a class="nounderline abstract_t">Lambert WE, De Leenheer AP, Van Bocxlaer JF, Piette M. Meprobamate intoxication: rare and difficult to find. J Toxicol Clin Toxicol 1992; 30:683.</a></li><li><a class="nounderline abstract_t">Charron C, Mekontso-Dessap A, Chergui K, et al. Incidence, causes and prognosis of hypotension related to meprobamate poisoning. Intensive Care Med 2005; 31:1582.</a></li><li><a class="nounderline abstract_t">Buire AC, Vitry F, Hoizey G, et al. Overdose of meprobamate: plasma concentration and Glasgow Coma Scale. Br J Clin Pharmacol 2009; 68:126.</a></li><li><a class="nounderline abstract_t">Gaultier M, Fournier E, Bismuth C, et al. [Acute poisoning by meprobamate. Apropos of 141 cases]. Bull Mem Soc Med Hop Paris 1968; 119:675.</a></li><li><a class="nounderline abstract_t">Mounier B, Pons B, Delavenne X, et al. [Severe meprobamate poisoning: description of 146 cases in a French department]. Therapie 2012; 67:183.</a></li><li><a class="nounderline abstract_t">Maignan M, Pommier P, Clot S, et al. Deliberate drug poisoning with slight symptoms on admission: are there predictive factors for intensive care unit referral? A three-year retrospective study. Basic Clin Pharmacol Toxicol 2014; 114:281.</a></li><li><a class="nounderline abstract_t">Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997; 280:1383.</a></li><li><a class="nounderline abstract_t">Roache JD, Griffiths RR. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 1987; 243:978.</a></li><li><a class="nounderline abstract_t">Heacock C, Bauer MS. Tolerance and dependence risk with the use of carisoprodol. Am Fam Physician 2004; 69:1622.</a></li><li><a class="nounderline abstract_t">Reeves RR, Carter OS, Pinkofsky HB, et al. Carisoprodol (soma): abuse potential and physician unawareness. J Addict Dis 1999; 18:51.</a></li><li><a class="nounderline abstract_t">Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: a drug of continuing abuse. J Am Osteopath Assoc 1997; 97:723.</a></li><li><a class="nounderline abstract_t">Verpooten GA, De Broe ME. Prediction of the efficacy of hemoperfusion and hemodialysis in severe poisoning. Arch Toxicol Suppl 1982; 5:304.</a></li><li class="breakAll">Hoizey G, Gozalo C, Canas F, Fornes P, Binet L, Thomas A, Oget O, HerveMillart, Lamiable D. Distribution tissulaire post-mortem du meprobamate: à propos de 8 cas. Ann Toxicol Anal 2008; 20:47.</li><li><a class="nounderline abstract_t">Bismuth C, Baud FJ, Galliot M, et al. [Liver metabolism of meprobamate: clinical estimation in acute intoxication]. J Toxicol Clin Exp 1985; 5:321.</a></li><li class="breakAll">Micromedex Healthcare Series. Thomson Reuters, Greenwood Village, Colorado, 2010.</li><li><a class="nounderline abstract_t">Maddock RK Jr, Bloomer HA. Meprobamate overdosage. Evaluation of its severity and methods of treatment. JAMA 1967; 201:999.</a></li><li><a class="nounderline abstract_t">HOLLISTER LE, LEVY G. KINETICS OF MEPROBAMATE ELIMINATION IN HUMANS. Chemotherapia (Basel) 1964; 9:20.</a></li><li><a class="nounderline abstract_t">Jacobsen D, Wiik-Larsen E, Saltvedt E, Bredesen JE. Meprobamate kinetics during and after terminated hemoperfusion in acute intoxications. J Toxicol Clin Toxicol 1987; 25:317.</a></li><li><a class="nounderline abstract_t">Landier C, Lanotte R, Legras A, et al. [State of shock during acute meprobamate poisoning. 6 cases]. Ann Fr Anesth Reanim 1994; 13:407.</a></li><li><a class="nounderline abstract_t">Allen MD, Greenblatt DJ, Noel BJ. Meprobamate overdosage: a continuing problem. Clin Toxicol 1977; 11:501.</a></li><li><a class="nounderline abstract_t">Eeckhout E, Huyghens L, Loef B, et al. Meprobamate poisoning, hypotension and the Swan-Ganz catheter. Intensive Care Med 1988; 14:437.</a></li><li><a class="nounderline abstract_t">Lhoste F, Lemaire F, Rapin M. Treatment of hypotension in meprobamate poisoning. N Engl J Med 1977; 296:1004.</a></li><li><a class="nounderline abstract_t">Mellerio F. Clinical and EEG study of a case of acute poisoning, with cerebral electrical silence followed by recovery. Electroencephalogr Clin Neurophysiol 1971; 30:254.</a></li><li><a class="nounderline abstract_t">Mellerio F, Frejaville JP, Gluckman JC. [Apropos of acute poisoning with meprobamate. An unusual electroclinical case]. Presse Med 1968; 76:2227.</a></li><li><a class="nounderline abstract_t">Tirot P, Harry P, Bouachour G, et al. [Electroencephalographic silence after intoxication with a carbamate tranquilizer]. J Toxicol Clin Exp 1991; 11:417.</a></li><li><a class="nounderline abstract_t">Lobo PI, Spyker D, Surratt P, Westervelt FB Jr. Use of hemodialysis in meprobamate overdosage. Clin Nephrol 1977; 7:73.</a></li><li><a class="nounderline abstract_t">Axelson JA, Hagaman JF. Meprobamate poisoning and pulmonary edema. N Engl J Med 1977; 296:1481.</a></li><li><a class="nounderline abstract_t">Bertran F, de la Sayette V, Lacotte J, et al. [Acute rhabdomyolysis and meprobamate poisoning]. Therapie 1992; 47:444.</a></li><li><a class="nounderline abstract_t">Bourry J, Sainty JM, Roux JJ, Ressiot G. [Acute pancreatitis in the course of meprobamate poisoning. Possible role of pressor amine therapy]. Nouv Presse Med 1976; 5:1918.</a></li><li><a class="nounderline abstract_t">Fathallah N, Zamy M, Slim R, et al. Acute pancreatitis in the course of meprobamate poisoning. JOP 2011; 12:404.</a></li><li><a class="nounderline abstract_t">Schwartz HS. Acute meprobamate poisoning with gastrotomy and removal of a drug-containing mass. N Engl J Med 1976; 295:1177.</a></li><li><a class="nounderline abstract_t">Delavenne X, Gay-Montchamp JP, Basset T. HPLC MS/MS method for quantification of meprobamate in human plasma: application to 24/7 clinical toxicology. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:215.</a></li><li><a class="nounderline abstract_t">Daval S, Richard D, Souweine B, et al. A one-step and sensitive GC-MS assay for meprobamate determination in emergency situations. J Anal Toxicol 2006; 30:302.</a></li><li><a class="nounderline abstract_t">Beveridge GW. Bullous lesions in poisoning. Br Med J 1971; 4:116.</a></li><li><a class="nounderline abstract_t">Dunn C, Held JL, Spitz J, et al. Coma blisters: report and review. Cutis 1990; 45:423.</a></li><li><a class="nounderline abstract_t">Hassan E. Treatment of meprobamate overdose with repeated oral doses of activated charcoal. Ann Emerg Med 1986; 15:73.</a></li><li><a class="nounderline abstract_t">Stack PE, Thomas E. Pharmacobezoar: an evolving new entity. Dig Dis 1995; 13:356.</a></li><li><a class="nounderline abstract_t">Meprobamate &amp; bezoar formation. Ann Emerg Med 1987; 16:472.</a></li><li><a class="nounderline abstract_t">Crome P, Higgenbottom T, Elliott JA. Severe meprobamate poisoning: successful treatment with haemoperfusion. Postgrad Med J 1977; 53:698.</a></li><li><a class="nounderline abstract_t">Hoy WE, Rivero A, Marin MG, Rieders F. Resin hemoperfusion for treatment of a massive meprobamate overdose. Ann Intern Med 1980; 93:455.</a></li><li><a class="nounderline abstract_t">Lin JL, Lim PS, Lai BC, Lin WL. Continuous arteriovenous hemoperfusion in meprobamate poisoning. J Toxicol Clin Toxicol 1993; 31:645.</a></li><li><a class="nounderline abstract_t">Laroche B, Hoang The Dan P, Lapandry C, et al. [Acute meprobamate poisoning. Efficacy of peritoneal dialysis]. Cah Anesthesiol 1984; 32:677.</a></li></ol></div><div id="topicVersionRevision">Topic 335 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13316694" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Three cases of meprobamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1433436" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meprobamate intoxication: rare and difficult to find.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence, causes and prognosis of hypotension related to meprobamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660012" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Overdose of meprobamate: plasma concentration and Glasgow Coma Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5685507" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [Acute poisoning by meprobamate. Apropos of 141 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850107" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Severe meprobamate poisoning: description of 146 cases in a French department].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23998644" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Deliberate drug poisoning with slight symptoms on admission: are there predictive factors for intensive care unit referral? A three-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067327" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3694540" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086035" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tolerance and dependence risk with the use of carisoprodol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334375" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Carisoprodol (soma): abuse potential and physician unawareness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9439144" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Carisoprodol: a drug of continuing abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6954915" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prediction of the efficacy of hemoperfusion and hemodialysis in severe poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6954915" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prediction of the efficacy of hemoperfusion and hemodialysis in severe poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880294" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : [Liver metabolism of meprobamate: clinical estimation in acute intoxication].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880294" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Liver metabolism of meprobamate: clinical estimation in acute intoxication].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6072491" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Meprobamate overdosage. Evaluation of its severity and methods of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14293424" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : KINETICS OF MEPROBAMATE ELIMINATION IN HUMANS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3669117" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Meprobamate kinetics during and after terminated hemoperfusion in acute intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992948" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [State of shock during acute meprobamate poisoning. 6 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/608316" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Meprobamate overdosage: a continuing problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3403779" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meprobamate poisoning, hypotension and the Swan-Ganz catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/846530" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of hypotension in meprobamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4103173" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical and EEG study of a case of acute poisoning, with cerebral electrical silence followed by recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5719470" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Apropos of acute poisoning with meprobamate. An unusual electroclinical case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1841078" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Electroencephalographic silence after intoxication with a carbamate tranquilizer].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/844228" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of hemodialysis in meprobamate overdosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/865525" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Meprobamate poisoning and pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1299996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : [Acute rhabdomyolysis and meprobamate poisoning].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/980709" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Acute pancreatitis in the course of meprobamate poisoning. Possible role of pressor amine therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737904" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute pancreatitis in the course of meprobamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/980021" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute meprobamate poisoning with gastrotomy and removal of a drug-containing mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185792" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : HPLC MS/MS method for quantification of meprobamate in human plasma: application to 24/7 clinical toxicology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839465" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A one-step and sensitive GC-MS assay for meprobamate determination in emergency situations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5097414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bullous lesions in poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2350978" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Coma blisters: report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3942359" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of meprobamate overdose with repeated oral doses of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8590522" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacobezoar: an evolving new entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826824" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Meprobamate&amp;bezoar formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/593997" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Severe meprobamate poisoning: successful treatment with haemoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436167" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Resin hemoperfusion for treatment of a massive meprobamate overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254705" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Continuous arteriovenous hemoperfusion in meprobamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6529684" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Acute meprobamate poisoning. Efficacy of peritoneal dialysis].</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
